Effects of Polycaprolactone-Tricalcium Phosphate, Recombinant Human Bone Morphogenetic Protein-2 and Dog Mesenchymal Stem Cells on Bone Formation: Pilot Study in Dogs
0
조회
0
다운로드
10
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to evaluate the survival, proliferation, and bone formation of dog mesenchymal stem cells (dMSCs) in the graft material by using Polycaprolactone-tricalcium phosphate (PCL-TCP), auto-fibrin glue (AFG), recombinant human bone morphogenetic protein-2 (rhBMP-2), and dMSCs after a transplantation to the scapula of adult beagle dogs. Materials and Methods: The subjects were two beagle dogs. Total dose of rhBMP-2 on each block was 10 μg with 50 μg/mg concentration. The cortical bone of the scapula of the dog was removed which was the same size of PCL-TCP block (Osteopore International Pte, Singapore; 5.0×5.0×8.0 mm in size), and the following graft material then was fixed with orthodontic mini-implant, Dual-top® (Titanium alloy, Jeil Co. Seoul, Korea). Four experimental groups were prepared for this study, Group 1: PCL-TCP + aFG; Group 2: PCL-TCP + aFG + dMSCs; Group 3: PCL-TCP + aFG + dMSCs + rhBMP-2; Group 4: PCL-TCP + aFG + dMSCs + rhBMP-2 + PCL membrane. The survival or proliferation of dMSCs cells was identified with an extracted tissue through a fluorescence microscope, H-E staining and Von-Kossa staining in two weeks and four weeks after the transplantation. Results: The survival and proliferation of dMSCs were identified through a fluorescence microscope from both Group 1 and Group 2 in two weeks and four weeks after the transplantation. Histological observation also found that the injected cells were proliferating well in the G2, G3, and G4 scaffolds. Conclusion: This study concluded that bone ingrowth occurred in PCL-TCP scaffold which was transplanted with rhBMP-2, and MSCs did not affect bone growth. More sufficient healing time would be needed to recognize effects of dMSCs on bone formation.
Abstract
Purpose: The aim of this study was to evaluate the survival, proliferation, and bone formation of dog mesenchymal stem cells (dMSCs) in the graft material by using Polycaprolactone-tricalcium phosphate (PCL-TCP), auto-fibrin glue (AFG), recombinant human bone morphogenetic protein-2 (rhBMP-2), and dMSCs after a transplantation to the scapula of adult beagle dogs. Materials and Methods: The subjects were two beagle dogs. Total dose of rhBMP-2 on each block was 10 μg with 50 μg/mg concentration. The cortical bone of the scapula of the dog was removed which was the same size of PCL-TCP block (Osteopore International Pte, Singapore; 5.0×5.0×8.0 mm in size), and the following graft material then was fixed with orthodontic mini-implant, Dual-top® (Titanium alloy, Jeil Co. Seoul, Korea). Four experimental groups were prepared for this study, Group 1: PCL-TCP + aFG; Group 2: PCL-TCP + aFG + dMSCs; Group 3: PCL-TCP + aFG + dMSCs + rhBMP-2; Group 4: PCL-TCP + aFG + dMSCs + rhBMP-2 + PCL membrane. The survival or proliferation of dMSCs cells was identified with an extracted tissue through a fluorescence microscope, H-E staining and Von-Kossa staining in two weeks and four weeks after the transplantation. Results: The survival and proliferation of dMSCs were identified through a fluorescence microscope from both Group 1 and Group 2 in two weeks and four weeks after the transplantation. Histological observation also found that the injected cells were proliferating well in the G2, G3, and G4 scaffolds. Conclusion: This study concluded that bone ingrowth occurred in PCL-TCP scaffold which was transplanted with rhBMP-2, and MSCs did not affect bone growth. More sufficient healing time would be needed to recognize effects of dMSCs on bone formation.
참고문헌 (27)
- Jeong SI, "In vivo biocompatibility and degradation behavior of elastic poly (L-lactide-co-epsilon-caprolactone) scaffolds", Biomaterials, 25, pp.5939~5946 (2004)
- Gabriel M, "Direct grafting of RGD-motifcontaining peptide on the surface of polycaprolactone films", J Biomater Sci Polym Ed, 17, pp.567~577 (2006)
- Rai B, "The effect of rhBMP-2 on canine osteoblasts seeded onto 3D bioactive polycaprolactone scaffolds", Biomaterials, 25, pp.5499~5506 (2004)
- Lee SJ, "Cytokine delivery and tissue engineering", Yonsei Med J, 41, pp.704~719 (2000)
- Pang EK, "Effect of recombinant human bone morphogenetic protein-4 dose of bone formation in a rat calvarial defect model", J Periodontol, 75, pp.1364~1370 (2004)
- Orban JM, "Composition options for tissue-engineered bone", Tissue Eng, 8, pp.529~539 (2002)
- Caplan AI, "Mesenchymal stem cells", J Orthop Res, 9, pp.641~650 (1991)
- Pittenger MF, "Multilineage potential of adult human mesenchymal stem cells", Science, 284, pp.143~147 (1999)
- Kim CS, "Ectopic bone formation associated with recombinant human bone morphogenetic proteins-2 using absorbable collagen sponge and beta tricalcium phosphate as carriers", Biomaterials, 26, pp.2501~2507 (2005)
- Barboza EP, "Ridge augmentation following implantation of recombinant human bone morphogenetic protein-2 in the dog", J Periodontol, 71, pp.488~496 (2000)
- Petite H, "Tissue-engineered bone regeneration", Nat Biotechnol, 18, pp.959~963 (2000)
- Yeo A, "Customizing the degradation and load-bearing profile of 3D polycaprolactone-tricalcium phosphate scaffolds under enzymatic and hydrolytic conditions", J Biomed Mater Res B Appl Biomater, 87, pp.562~569 (2008)
- Rai B, "Novel PCLbased honeycomb scaffolds as drug delivery systems for rhBMP-2", Biomaterials, 26, pp.3739~3748 (2005)
- Rai B, "An in vitro evaluation of PCL-TCP composites as delivery systems for platelet-rich plasma", Control Release, 107, pp.330~342 (2005)
- Chiapasco M, "Clinical outcome of autogenous bone blocks or guided bone regeneration with e- PTFE membranes for the reconstruction of narrow edentulous ridges", Clin Oral Implants Res, 10, pp.278~288 (1999)
- Rah DK, "Art of replacing craniofacial bone defects", Yonsei Med J, 41, pp.756~765 (2000)
- Song L, "Mesenchymal stem cell-based cartilage tissue engineering: cells, scaffold and biology", Cytotherapy, 6, pp.596~601 (2004)
- Kawabata M, "Signal transduction by bone morphogenetic proteins", Cytokine Growth Factor Rev, 9, pp.49~61 (1998)
- Chen D, "Bone morphogenetic proteins", Growth Factors, 22, pp.233~241 (2004)
- Deckers MM, "Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A", Endocrinology, 143, pp.1545~1553 (2002)
- Bösch P, "Experimental investigations of the effect of the fibrin adhesive on the Kiel heterologous bone graft", Arch Orthop Traumat Surg, 96, pp.177~185 (1980)
- Isogai N, "Experimental use of fibrin glue to induce site-directed osteogenesis from cultured periosteal cells", Plast Reconstr Surg, 105, pp.953~963 (2000)
- Reiss RF, "Autologous fibrin glue: production and clinical use", Transfusi Med Rev, 10, pp.85~92 (1996)
- Yoshida H, "A quicker preparation method for autologous fibrin glue", Biol Pharm Bull, 21, pp.1367~1370 (1998)
- Thorn JJ, "Autologous fibrin glue with growth factors in reconstructive maxillofacial surgery", Int J Oral Maxillofac Surg, 33, pp.95~100 (2004)
- Orban JM, "Composition options for tissue-engineered bone", Tissue Eng, 8, pp.529~539 (2002)
- Patel VV, "Controlling bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth using fibrin glue", Spine, 31, pp.1201~1206 (2006)